Background and Purpose-Beyond the Framingham Stroke Risk Score, prediction of future stroke may improve with a genetic risk score (GRS) based on single-nucleotide polymorphisms associated with stroke and its risk factors. Methods-The study includes 4 population-based cohorts with 2047 first incident strokes from 22 720 initially stroke-free European origin participants aged ≥55 years, who were followed for up to 20 years. GRSs were constructed with 324
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S troke is a major and debilitating neurological disease that increases in frequency with age; it is estimated that in 2030, 23 million persons will have a first-ever stroke resulting in 7.8 million deaths. 1, 2 Stroke is a complex disease with many modifiable risk factors and a substantial genetic component, with heritability estimates varying from 17% 3 to 38%. 4 The genetic architecture of stroke has been difficult to unravel. Although recently some findings have been replicated for specific stroke subtypes, 5, 6 initial discoveries of genetic variants from genome-wide association studies (GWASs) of all stroke (subtypes combined) outcome 7 have failed to replicate. This has led to the concept that different genes may be involved in different subtypes of stroke.
In contrast, many modifiable clinical and epidemiological risk factors consistently have been shown to increase the risk for stroke and also have well replicated risk-associated genetic variants (single-nucleotide polymorphisms [SNPs] ). Several modifiable risk factors have been combined into validated clinical prediction tools such as the Framingham Stroke Risk Score (FSRS), which incorporates systolic blood pressure, diabetes mellitus, cigarette smoking, prior cardiovascular disease, atrial fibrillation, left ventricular hypertrophy, and the use of antihypertensive medications. 8, 9 The FSRS measures traits that may fluctuate in the short or medium term, thus affecting its predictive properties in any 1 individual. Insufficiency of the FSRS has been demonstrated in earlier studies. 10 Given the increasing availability of genotyping technology and the promise of using the information in a more personalized medicine approach, it is timely to investigate whether risk scores incorporating genetic information will add to the power to predict an individual's future risk for stroke.
Here, we examine the predictive properties of a genetic risk score (GRS) to predict future stroke in community-dwelling stroke-free individuals. We hypothesized that the combined effect of individual SNPs with small effects would improve prediction. A previous study by Kathiresan et al 11 found that a GRS based on SNPs from a single class of risk factors, lipids, did have some value in reclassification but not in improved discrimination of persons at future risk for cardiovascular disease. However, cardiovascular diseases such as stroke have a complex pathophysiology, which can partially be accounted for in GRS, as they are in clinical risk scores. Here, we take the approach of including in a risk score, genetic variants associated with stroke and its multiple risk factors, with the goals of assessing the potential of a score, based on SNPs associated with stroke and its risk factors, to predict stroke in general populations and investigating whether the score could potentially add to the predictability of a score based on established stroke clinical and epidemiological risk factors. As far as we know, we are the first to try to combine not only a disease-specific or risk factor-specific set of SNPs into a risk score, but also a comprehensive set of risk SNPs from the whole spectrum of nonbehavioral risk factors for stroke. We also investigated the performance of the GRS in a higher risk population captured in a clinic-based case-control study of ischemic stroke (IS).
Materials and Methods
Our analyses are based on incident cases and stroke-free participants characterized in 4 cohorts participating in the Cohorts for Heart and Ageing Research in Genomic Epidemiology (CHARGE) consortium. CHARGE is a large consortium of major population-based prospective cohort studies of cardiovascular health that aims to identify new genetic variants for multiple quantitative, subclinical, and clinical factors contributing to health and disease in older persons. 12 The individual cohorts and the combined CHARGE GWAS of stroke genes have been previously described. 7
Cohorts and Case Definition
This analysis is based on the following CHARGE cohorts: the Atherosclerosis Risk in Communities (ARIC) study, 13 the Cardiovascular Health Study (CHS), 14 the Framingham Heart Study (FHS), 15, 16 and the first cohort of the Rotterdam Study (RS). 17 From these cohorts, we included persons who were stroke free at the age of ≥55 years, of European descent, and who had complete outcome and genotype data ( Table 1 , Table I in the online-only Data Supplement). For all cohorts, the baseline was established in the late 1980s and early 1990s, and all studies are ongoing. All participants provided informed consent, and all studies were approved by their governing institutional review boards.
All cohorts defined stroke as a focal neurological deficit of presumed vascular cause with a sudden onset and lasting for ≥24 hours or until death if the participant died <24 hours after the onset of symptoms. All suspected events were adjudicated by stroke experts who reviewed medical records, death certificates, imaging studies, or some combination of these sources. We report on all stroke, which includes ischemic, hemorrhagic, and unknown subtype and separately on IS, which is of presumed cardioembolic/large vessel/small vessel origin. Subarachnoid hemorrhages were excluded from all analyses. single-nucleotide polymorphisms implicated in stroke and 9 risk factors. The association of the GRS to first incident stroke was tested using Cox regression; the GRS predictive properties were assessed with area under the curve statistics comparing the GRS with age and sex, Framingham Stroke Risk Score models, and reclassification statistics. These analyses were performed per cohort and in a meta-analysis of pooled data. Replication was sought in a case-control study of ischemic stroke.
Genotyping
Each study separately genotyped or imputed SNPs to the same reference panel (see Table II in the online-only Data Supplement for methods) and provided data on imputation quality. Because of imputation, there were no missing genotypes in the data sets. Genotypes for each SNP were coded in terms of the number of risk alleles.
Identifying Risk Factors and Associated SNPs and Selecting SNPs for Inclusion in the Risk Score

SNP Selection
Based on a literature review, as well as clinical and neurological expert opinion, we identified 9 domains of established risk factors for stroke that have also been studied in GWASs: high blood pressure, atherosclerosis, arrhythmia, diabetes mellitus, inflammation, blood constituents, hematologic changes, obesity, elevated lipids, and impaired kidney function. Within each of these risk factor domains, we identified 3 to 5 traits that contribute to the overall domain (Table 2) , resulting in a total of 33 traits. For each of the 33 traits, we identified from published, in press, and under review GWASs SNP variants that associated with the trait at the standard GWAS significance level (P=5×10 −8 ) and for which there was evidence of independent replication (see Table III in the online-only Data Supplement for a complete list of references). We also included 2 IS-associated SNPs identified and replicated by the International Stroke Genetics Consortium. 5 Although these 4 CHARGE cohorts were often included in the above-referenced trait GWAS, in general the meta-analyses were based on many more subjects, with the proportion of subjects from these studies ranging between 0 18 and ≈86%. 19 In total, we identified 334 autosomal SNPs for 34 traits (including stroke). When several SNPs for a class of risk factors were located in the same loci, we selected the top SNP with the lowest P value from the most recent meta-analyses that included the largest number and thus had the largest power and highest precision. In some cases, the same SNP was associated with multiple traits. For this, we assigned the SNP to the clinical rather than the subclinical trait (eg, diabetes mellitus over fasting glucose levels). After these exclusions, we included 324 SNPs (see Table III in the online-only Data Supplement), including 28 traits with multiple SNPs and 6 with single SNPs.
Statistics: Construction of the Risk Score
The construction of the risk score ( Figure 1 ) is described in detail in the Methods in the online-only Data Supplement. In short, weighted risk scores were created for each of the 28 traits with multiple SNPs. Weights were the effects, or log odds ratios, of the risk allele on the outcome to which it was originally associated. This effect was multiplied by the number of risk alleles (allele dosage: 0, 1, or 2) the individual carried; for imputed SNPs, where the dosage is estimated, this value can obtain any fraction between 0 and 2. The risk score was the sum of the weight×dosage product for all SNPs within the trait. For the traits that had only 1 SNP associated (singletons), the allele dosage was used. Risk scores and singletons were entered as covariates in Cox regressions with age as the time-to-event variable. Each cohort calculated a modified FSRS (mFSRS), which differed from the original FSRS only in the omission of the age variable.
Analysis
The individual risk predictions were calculated from 5 regression models: model 1 included only sex; model 2 included the GRS only; model 3 included sex and the GRS; model 4 included sex and the 
Calculation and Comparison of the Receiver Operating Characteristic Curves
Receiver operating characteristic curves with corresponding areas under the curve (AUCs; 95% confidence interval for each model) were created from the predicted risks derived from the regression models. The model AUCs were tested against the null model (AUC=0.50) and compared with each other. The latter comparisons were tested with the Hanley-McNeil test for comparison of correlated AUCs. 20 The Hanley-McNeil test requires a correlation between the AUCs, which was obtained using the metacor package for R. 21 Finally, we estimated meta-AUCs (95% confidence intervals) based on all cohorts combined using an inverse variance weighted meta-analysis.
Reclassification Statistics
In secondary analyses, we assessed the added clinical value of the GRS over the FSRS using 2 statistics: the net reclassification improvement (NRI) without cutoff values (continuous NRI), which gives a summary of the number of subjects with reclassified predicted case status based on the new score, and the integrated discrimination improvement (IDI), 22, 23 which describes the ability of the score to discriminate between cases and noncases.
External Replication
We investigated the predictive power of the same GRS in a German case-control set of IS previously described. 5, 6 Cases (n=985) were the German samples of the Wellcome Trust Case Control Consortium 2 (WTCCC2), recruited in the Klinikum Grosshadern, Department of Neurology, Ludwig-Maximilians-Universität in Munich, Germany. Controls (n=596) were participants in the Kooperative Gesundheitsforschung in der Region Augsburg, Genetikplatform (KORA-gen) study, residing in the Augsburg area in Germany (http:// epi.helmholtz-muenchen.de/kora-gen/index_e.php), with no history of stroke or transient ischemic attack. The studies were approved by the respective local institutional review boards, and all subjects gave informed consent. Details on genotyping and imputation are given in Table II in the online-only Data Supplement. To account for the casecontrol design, we used a logistic regression model, adjusted for age and sex to estimate the trait scores and their association with stroke. Because details on the elements of the FSRS were not generally available for the subjects in this cohort, we were unable to perform replication efforts for the FSRS comparisons in this cohort.
Results
During follow-up, 2047 participants from the 22 720 developed first-ever strokes, including 1523 ISs. The RS (No. of cases=783; 13.5%) and CHS (No. of cases=560; 17.1%) participants were older and had more incident stroke events (Table 1 ) than the FHS (No. of cases=206; 4.8%) and ARIC study (No. of cases=498; 5.3%) participants. These cohorts also had a higher prevalence of hypertension than the other 2. Most smokers were found in ARIC study and RS ( Table  I in Predicted risks from the models including the GRS and mFSRS were significantly higher in cases than in individuals who remained stroke free (P<0.001, Table IV in the online-only Data Supplement). Across cohorts, the AUC including only the GRS (Tables 3 and 4, Figure II in the online-only Data Supplement) ranged from 0.563 to 0.617 for all stroke. When combining the findings of the cohorts, the meta-AUC was 0.578 (P=9×10 −10 compared with the model with only sex). For the model with sex and the GRS, the all stroke meta-AUC was 0.572, which was statistically different from the model including only sex (P=9×10 −18 ). For IS, the AUC of the model including only the GRS ranged from 0.585 to 0.627 across cohorts; the meta-AUC was 0.592. For the combined model with sex and the GRS, meta-AUC was 0.597 (P value compared with sex only=2×10 −19 ; Tables 5 and 6, Figure II in the online-only Data Supplement).
Comparison Between the Genetic and Clinical Risk Scores
In all cohorts, the AUC for the mFSRS was higher than those seen for the GRS. For all stroke, the mFSRS AUC ranged from 0.587 in the RS to 0.709 in the FHS, with a highly significant Figure III in the onlineonly Data Supplement). In all cohorts, there was a low correlation between the absolute predicted risks derived from mFSRS and those derived from the GRS (metacorrelation, 0.012; meta P=0. 13 ). The full model (sex, mFSRS, and the GRS) improved prediction significantly in all cohorts except the FHS, the cohort that was used to develop the original FSRS. The meta-AUC for the full model was 0.637. When the full model is compared with the model with sex and mFSRS, the GRS gives an improvement of 0.016 (P=2×10 −6 ) over classical risk factors. For IS, the meta-AUC for the full model was 0.654, with an improvement of 0.021 (P=4×10 −7 ) between the full model and the sex and mFSRS model (Tables 5 and 6, Figure 2 ). Compared with the model based on sex and the FSRS, the GRS yielded a significant NRI (improvement ranging from 0.18 to 0.32 for all stroke and from 0.24 to 0.28 for IS, P≤1.1×10 −4 ) and IDI (improvement ranging from 0.005 to 0.02 for all stroke and from 0.008 to 0.021 for IS, P≤5×10 −5 ; Table V in the online-only Data Supplement).
Replication
We replicated our findings in the case-control sample of the WTCCC2. The AUC of the sex, age, and GRS model was higher than the AUC of the model with age and sex alone (difference between the 2 models=0.014; P=0.04; Table VI and Figure IV in the online-only Data Supplement). The reclassification statistics (continuous NRI=0.309; P<1×10 −5 and IDI=0.018; P<1×10 −5 ) showed a small but highly significant improvement in prediction of IS when the GRS was added to models based on age and sex. 
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Discussion
We assessed the predictive properties of a GRS based on stroke risk factors in a population-based sample of 2047 well-characterized incident stroke cases among 22 720 initially stroke-free individuals. We found that a GRS that included genome-wide associated SNPs for 9 domains of risk factors plus stroke provided a small but very significant and consistent improvement in the prediction of an individual's risk for future stroke. This small difference was observed when the GRS was compared with sex-adjusted models as well as with a widely used clinical-epidemiological risk score. Similar results were found when the score was applied in a large clinic-based case-control sample. Age is an important predictor of many diseases, in particular a late-onset outcome as stroke. A large part of the discrimination of a prediction model is therefore determined by age, biasing the interpretation of the value of the other variables, in our case genetic predictors. In this study, we controlled for age as the follow-up time, so we could clearly assess whether genetic information could improve prediction conditional on the person's age. It is important to note that the AUCs are therefore in general lower than that reported in the literature. For instance, in the RS, we find much lower AUCs in the Cox approach with age as the timescale (AUC for FSRS=0.59; P=1×10 −14 ) than in the logistic model in which age is a covariate, essentially examining the GRS with all subjects of the mean age (AUC for FSRS=0.65; P=2×10 −39 ).
The GRS performs significantly worse than the age+sex model in the replication, but this was not the primary comparison we wished to test. Our goal was to test whether the GRS has added value over and above the clinical risk factors, and we do indeed find modest (ΔAUC [discovery]=0.021; ΔAUC
[replication]=0.024) but significant (P [discovery]=3.66×10 −7 ; P [replication]=0.03; Tables 5 and 6 and Table VI in the online-only Data Supplement) improvement in the AUCs in both the discovery and replication analyses. The difference in P values most likely reflects the differences in sample size of the discovery and replication cohorts.
Before interpreting the findings, it is important to note the assumptions underlying the construction of the score and consider the limitations: (1) the relationships between variants and risk factors and between risk factor and outcome are always the same, that is, (log)linear; (2) each variant associated with the stroke risk factor will also be a risk variant for stroke; (3) the effect is proportional to the number of risk variants (0, 1, 2), whereas in reality, the variant may have a dominant or recessive effect on stroke); and (4) there is no interaction between genetic variants (we did not find evidence for interaction between the loci in this study). Each of these assumptions is necessary when creating such a score, but they may be simplifications of the true underlying biological model.
Previous studies have examined the association of clinical disease to SNPs that associate with risk factors for the disease. For example, studies by Ehret et al 24 and Wain et al 25 showed that genetic variants associated with blood pressure traits were also associated with stroke. Paynter et al 26 assessed the performance of a GRS based on a small number of SNPs associated with cardiovascular disease to predict cardiovascular disease outcomes including stroke. They did not find that their GRS improved prediction over the traditional risk factors. A similar conclusion has been reached by other investigators examining risk SNPs for a single class of risk factors, 11, 27, 28 although recently some authors have found risk differences between GRS quintiles for stroke. 29, 30 Here, we present a different approach: we test a single outcome (stroke) to a risk score based on SNPs associated with a variety of risk factors. This approach takes into account the complexity of disease, and our results suggest that incorporating such genetic information into risk scores may be fruitful even in a complex disease such as stroke.
Our analyses showed that the GRS improved the discrimination over the mFSRS, although the absolute increase in prediction was small. The correlation between the mFSRS and GRS was low, suggesting the genetic variants, which are constant over the lifetime, can add to the information provided by a single assessment of fluctuating risk factors such as blood pressure and glucose levels. Supporting evidence of this improvement is reflected in the improved reclassification statistics. Although reclassification is seen as clinically relevant, this finding should be interpreted with caution because the value of the IDI has been questioned 31 and both the IDI and NRI may be inflated. 32 One of the most notable findings is that the GRS worked similarly in 3 of the 4 different cohorts, which, although all population based, had different age distributions. The absence of an improvement in prediction in the FHS beyond the mFSRS may well reflect overfitting of the mFSRS in this cohort, as the original FSRS was developed on the FHS source population. Another important finding is that AUCs and AUC improvements are higher and P values are lower for IS compared with all stroke, despite a smaller number of cases. This difference may reflect the fact that IS is a pathogenetically more homogenous phenotype, and the risk factors we selected are better associated to IS than to all stroke. This is consistent with GWAS discoveries which thus far have been limited to defined subtypes. 5, 6 It will be valuable to have both better clinical prediction models and improved genetic prediction models targeting ischemic and hemorrhagic stroke as 2 distinct clinical entities, resulting in an improvement to the FSRS, which has a low AUC. The combined clinical, genetic, and epidemiological risk model may become a valuable tool for clinicians, and such differential risk models for ischemic versus hemorrhagic stroke may even help guide treatment decisions.
Because array-based genotyping becomes more and more affordable and widely available, the possibility of multimarker genetic risk profiling as part of daily medical practice becomes more realistic. As we show in this article, clinical risk profiling alone is still superior in predictive power to genetic risk profiling alone in the setting of a populationbased cohort study of middle-aged and elderly subjects. In current clinical practice, some risk factors such as diabetes mellitus, hypertension, dyslipidemia, and atrial fibrillation often come to light only after a stroke has occurred. Paroxysmal atrial fibrillation may be missed during regular ECG registration or even during a 24-hour Holter monitoring. To act pre-emptively on these risk factors, a subject would have to be screened on a regular basis and at least every few years depending on their age and perhaps other factors; we suggest that their genetic profile might help select persons at higher stroke risk for more frequent or thorough screening. A GRS could be estimated at a single time point early in life, and persons with a higher genetic risk be targeted for more rigorous lifestyle counseling before risk factors emerge, more stringent clinical follow-up for control of risk factors, and even preventive medication such as platelet aggregation inhibitors, statins, or antihypertensive medications in persons with borderline levels of these risk factors. We anticipate that with rapid developments in unraveling the genetic origin of various stroke risk factors, the genetic prediction of stroke 
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February 2014 risk will improve in the near future, improving the efficacy of early genetic risk profiling and targeted preventive interventions. This study in a large prospectively followed population-based epidemiological cohort yields a proof of principle that genetic variants associated with risk factors for stroke combined into a risk score improves discrimination of at-risk patients. These results are based on stroke-free individuals living in the community who may be examined in first-line health services and are replicated in individuals who have had a stroke and are identified in the hospital setting. However, the small improvement we found is unlikely to be of clinical significance and only brings a small improvement over scores based on clinical information. In the future, however, as our understanding of the genetic architecture of stroke-its subtypes and risk factors-improves, GRS could become powerful additions to clinically measured risk factors. 
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Online Methods
The following information was extracted for each SNP: rs number and locus information; the risk and reference alleles and the risk allele frequency; and the effect size (beta SNP ) of the SNP association to the trait. All betas were calculated with the protective allele as the reference allele. Each cohort developed their own GRS following a standard analytical protocol (see Figure 2) : First, for each study participant, a specific (weighted) effect for each trait SNP was calculated by multiplying the reported beta SNP with the number of risk alleles carried by the individual. For the 28 traits with multiple SNPs the PredictABEL package in R 1 was used to combine the weighted SNP effects into a trait score. The other 6 trait scores included only one SNP.
In the second step, each of the 28 trait scores and the six singleton SNP genotypes [hereafter referred to as the GRS] were entered as parameters into a single Cox proportional hazards regression model [Survival package in R] 2 to estimate their association (beta trait ) with the time-to-event stroke outcome ( Supplemental Table III ). In the Cox model we used age as the time-to-event follow-up time scale. By using age as the time scale, we compared the cases to stroke-free participants who were the same age; this effectively controls for age in the Cox regression. Baseline age was the age at which subjects entered the cohort (RS, ARIC, CHS) or had blood drawn for genotyping (FHS). Follow-up time ended at the age when a first stroke (case) or death occurred, or at the age at the last confirmed disease-free visit (stroke-free participants). This model also accounted for left-truncation, which corrects for the bias introduced by including in the baseline cohort only individuals who survived long enough to enter the study 3 . In the third step an individual's predicted risk for future stroke was calculated with the model: beta trait1 * individual trait score1 + …+ beta trait34 * individual trait score34. Finally, each cohort calculated a modified FSRS (mFSRS) following the instructions by the score developers, with the only difference compared to the original FSRS being that age was not included because it was incorporated into the Cox models as the time scale for follow-up time. The mFSRS included information on systolic blood pressure, diabetes mellitus, cigarette smoking, prior cardiovascular disease, atrial fibrillation, left ventricular hypertrophy and the use of hypertensive medication. As is the case in the original calculations, there were separate scores for men and women. Never smoker (%) 40 48 86** 38 *Hypertension: Systolic blood pressure of 140 or more, diastolic blood pressure of 90 or more, or antihypertensive medication; Diabetes: blood glucose over 11 mmol/liter (20 mg/dl) non-fasting, 7 mmol/l (126 mg/dl) fasting, or the use of insulin or oral hypoglycemic agents **past smoking data not available for FHS; 86% current nonsmokers 6 Supplemental Table II 
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